Bayer Aktiengesellschaft (WSE:BAY)
Poland · Delayed Price · Currency is PLN | Market Cap | 152.84B +69.6% |
| Revenue (ttm) | 192.30B -2.2% |
| Net Income | -15.27B |
| EPS | -15.55 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 8.51 |
| Dividend | 0.47 (0.27%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | 149 |
| Average Volume | 66 |
| Open | 160.06 |
| Previous Close | 153.08 |
| Day's Range | 155.94 - 161.98 |
| 52-Week Range | 79.48 - 198.18 |
| Beta | n/a |
| RSI | 31.65 |
| Earnings Date | Mar 4, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial numbers in EUR Financial StatementsNews
Bayer Aktiengesellschaft (BAYRY) Q4 2025 Earnings Call Transcript
Bayer Aktiengesellschaft (BAYRY) Q4 2025 Earnings Call Transcript
Bayer AG (BAYRY) Q4 2025 Earnings Call Highlights: Strong Financial Performance Amid Challenges
Bayer AG (BAYRY) Q4 2025 Earnings Call Highlights: Strong Financial Performance Amid Challenges
Bayer's $7.25 billion Roundup settlement gets initial OK from Missouri judge
A state court judge in Missouri gave an initial green light on Wednesday to a proposed $7.25 billion settlement to resolve thousands of lawsuits claiming Bayer's Roundup weedkiller causes cancer.
Q4 2025 Bayer AG Earnings Call Transcript
Q4 2025 Bayer AG Earnings Call Transcript
Bayer (BAYRY) Secures Preliminary Approval for $7.25 Billion Roundup Settlement
Bayer (BAYRY) Secures Preliminary Approval for $7.25 Billion Roundup Settlement
Bayer (BAYRY) Shares Decline Amid Lower Earnings Forecast and Legal Settlements
Bayer (BAYRY) Shares Decline Amid Lower Earnings Forecast and Legal Settlements
DAX Eyes Bullish Recovery After 6% Slide and Retest of Psychological 24000 Handle
DAX is attempting a recovery following a 6% drop. The global energy shock is fueling stagflation anxiety, notably causing a record 12% plummet in the South Korean KOSPI index. Market performance is mi...
Trade Idea: DAX eyes bullish recovery after 6% slide and retest of psychological 24000 handle
DAX is attempting a recovery after a 6% slide, driven by Middle East conflict-induced energy price surges (oil +14.5% this week, EU gas +60%). The article analyzes the market's trajectory, risk of sta...
New FDA 510(k) Clearance Expands Bayer's MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (...
Bayer Forecasts â¬9.6B--â¬10.1B Profit as Roundup Litigation Uncertainty Persists
Bayer Forecasts â¬9.6B--â¬10.1B Profit as Roundup Litigation Uncertainty Persists
Bayer AG (BAYZF) Reports Q4 Earnings and 2026 Outlook
Bayer AG (BAYZF) Reports Q4 Earnings and 2026 Outlook
Bayer Q4 Loss Widens On Litigation Charges, Weak Sales; Warns On FY26
(RTTNews) - Bayer AG (BAYRY.PK, BAYZF.PK) reported Wednesday a hefty loss in its fourth quarter, wider than last year, amid high special charges for litigations and weak sales. The German pharmaceutic...
Bayer Net Loss Widens on Weedkiller Litigation Charges
The agriculture and pharmaceutical company reported a steeper net loss, including a €3.55 billion hit mainly from litigation-related expenses.
Oversold Conditions For Bayer (BAYZF)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer
LLY, JNJ, SNY and BAYRY ride strong pipelines and M&A momentum as Large-Cap Pharma rebounds in 2026 despite pricing and patent risks.
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, BAYRY and Sanofi are worth retaining as the industry shows some recovery.
Bayer (BAYRY) Reports Promising Phase 1 Results for Targeted Cancer Therapy
Bayer (BAYRY) Reports Promising Phase 1 Results for Targeted Cancer Therapy
Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
BERLIN--(BUSINESS WIRE)--Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary ef...
Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of 225Ac-PSMA-Tril...
Bayer's (BAYRY) Xofigo Combo Shows 24% Survival Benefit in mCRPC Trial
Bayer's (BAYRY) Xofigo Combo Shows 24% Survival Benefit in mCRPC Trial
Bayer's XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer's XOFIGO® plus enzalutamide demonstrates significant OS benefit in PEACE-3 trial in patients with mCRPC with bone metastases.
Bayer’s XOFIGO (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases
Final results from the pivotal investigational Phase III PEACE-3 trial demonstrate that first-line treatment with XOFIGO (radium-223 dichloride) in combination with enzalutamide, an androgen receptor ...
Lawyers for US cancer sufferers challenge Bayer’s $7.25bn Roundup settlement deal
Proposed settlement would pay users of glyphosate-based weedkiller who have non-Hodgkin lymphoma $10,000 to $165,000 A group of 14 law firms representing nearly 20,000 plaintiffs is seeking to interve...
Some roundup plaintiffs seek to delay preliminary approval of proposed $7.25 bln bayer settlement, court filing shows
Law firms representing nearly 20,000 people who sued Bayer over alleged injuries from its Roundup weedkiller urged a Missouri judge on Wednesday to delay reviewing the German company's proposed $7.25 ...